Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and HPA Axis Suppression of IDP-118 and HP Monad in Psoriasis
NCT03058744Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Halobetasol propionate 0.05% lotion and tazarotene in plaque psoriasis (4 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Local Skin Reactions at 8 Weeks. Started Apr 2015; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotiontazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03058744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058744.